查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1970819

非注射胰島素市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、通路、地區和競爭格局分類，2021-2031年

Non-Injectable Insulin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球非注射胰島素市場預計將從 2025 年的 36.9 億美元成長到 2031 年的 64.6 億美元，複合年成長率為 9.78%。

此市場領域專注於替代給藥途徑，例如肺部吸入和口服製劑，旨在無需使用侵入性針頭即可給藥。推動這一成長的主要因素是全球糖尿病患者人數的不斷增加，以及提高患有針頭恐懼症和注射疲勞患者的治療依從性的迫切需求。根據國際糖尿病聯盟的數據，到2025年，全球將有約5.89億成年人患有糖尿病，如此龐大的患者群體推動了對便捷替代療法的巨大需求，這些療法能夠克服與傳統皮下注射相關的生理和心理障礙。

市場概覽
預測期 2027-2031
市場規模：2025年 36.9億美元
市場規模：2031年 64.6億美元
複合年成長率：2026-2031年 9.78%
成長最快的細分市場 藥局
最大的市場 北美洲

儘管非注射藥物對患者生活品質的益處顯而易見，但市場仍面臨一個重大障礙：與標準注射藥物相比，非注射藥物的生物利用度較低。這種生理限制通常需要更高的劑量才能達到相同的治療效果，從而顯著增加生產成本，最終加重患者的負擔。因此，嚴格的報銷機制和與這些治療相關的高昂經濟負擔成為市場成長的主要障礙，阻礙了成本敏感地區的臨床應用。

市場促進因素

非注射胰島素產業的主要驅動力是全球糖尿病發生率的上升。這導致人們越來越需要提高患者的治療順從性，因為他們每天都要承受注射帶來的心理和生理負擔。疾病盛行率的上升推動了擴充性、易於使用且能緩解針頭恐懼症的治療方法的需求。國際糖尿病聯盟 (IDF) 的《IDF 糖尿病地圖集》（第 11 版）預測，到 2050 年，糖尿病成人患者人數將達到約 8.53 億，這凸顯了替代給藥系統的重要性。這種需求的規模也反映在大型製藥公司的業務規模上。例如，截至 2024 年，諾和諾德為超過 4,520 萬名患有嚴重慢性疾病的患者提供服務，這表明等待非侵入性治療方法的患者群體規模龐大。

同時，對替代胰島素製劑研發投入的增加正在推動整個產業的發展。製藥公司正積極投資吸入和口服給藥系統的創新，以克服傳統的生物利用度問題並提高治療效果。這些資金投入對於引導新技術從臨床試驗走向商業化至關重要。一個顯著的例子是，2025年2月，Oramed Pharmaceuticals宣布成立一家總額達7,500萬美元的策略合資企業，旨在加速其口服胰島素平台的開發和商業化。如此大規模的資金注入凸顯了該行業對非侵入性解決方案的承諾，並有望透過實現無痛胰島素給藥，推動下一階段的市場擴張。

市場挑戰

全球非注射胰島素市場成長面臨的主要障礙之一是肺部給藥和口服製劑的生物利用度低於標準注射製劑這一生理問題。由於這些替代給藥途徑難以有效穿過生物屏障，生產商必須配製含有更高濃度活性胰島素的藥物，以確保患者獲得必要的治療劑量。活性成分的增加直接推高了生產成本，導致最終價格顯著上漲，從而限制了保險公司和患者的購買力。

這種價格差異在醫療預算本已捉襟見肘的地區構成了一大障礙。嚴格的報銷政策往往優先考慮價格較低的傳統注射藥物，導致價格昂貴的非注射藥物缺乏足夠的健保覆蓋。近期有關糖尿病經濟影響的統計數據凸顯了這種經濟壓力的規模。根據國際糖尿病聯盟（IDF）預測，到2025年，全球糖尿病醫療費用支出將至少達到1兆美元。鑑於如此龐大的現有成本，支付方對引入高價療法仍然持謹慎態度，導致這些療法在臨床實踐中的普及程度有限，並阻礙了對成本敏感地區的市場成長。

市場趨勢

目前，市場格局正因超速效吸入式胰島素的出現而發生重塑。這種趨勢優先考慮那些能夠比傳統皮下注射更精確地模擬健康胰臟生理胰島素激增的製劑。這一趨勢強調最佳化乾粉製劑的動態粒徑，以確保藥物能夠深層沉積於肺部並快速被全身吸收，從而降低餐後高血糖的風險。製造商正有效地將這種藥物動力學優勢轉化為商業性成功，從而支撐了市場對速效、非侵入性替代療法的需求。例如，Mankind公司在2024年11月發布的2024年第三季財報中宣布，Afrezza的淨銷售額已增至1500萬美元，這表明吸入療法呈現明顯的成長態勢，其成長動力來自不斷成長的患者需求以及毛利潤向淨利潤轉化率的提高。

同時，口服和舌下胰島素噴霧劑的創新也在加速發展。研究人員正在開發利用新型胜肽載體的技術，以穿透黏膜屏障，同時避免與胃腸道給藥相關的分解問題。這一趨勢的重點是開發用於舌下給藥的液體製劑，這種製劑可以透過豐富的血管網路直接進入血液，繞過肝臟的首過代謝，而肝臟首過代謝常常導致口服藥物失效。這項技術進步直接滿足了加拿大眾多尋求無痛治療方案的患者的需求。正如不列顛哥倫比亞大學在其2024年6月發表的報導《不列顛哥倫比亞大學開發的口服胰島素滴劑為糖尿病患者帶來福音》中所指出的那樣，這些新型舌下滴劑是專門為幫助1170萬加拿大糖尿病或糖尿病前期患者而設計的，凸顯了此類粘膜給藥創新在區域市場的巨大潛力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球非注射型胰島素市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品類型（片劑、噴霧劑、其他）
    • 分銷通路（醫院藥局、網路藥局、藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美非注射用胰島素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲非注射用胰島素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區非注射胰島素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲非注射胰島素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲非注射胰島素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球非注射胰島素市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Midatech Pharma Plc
  • Shreya Life Sciences Pvt. Ltd.
  • Boston Therapeutics, Inc.
  • Coromed, Inc.
  • Diabetology Ltd.
  • Emisphere Technologies, Inc.
  • Oramed Pharmaceuticals, Inc.
  • Diasome Pharmaceuticals, Inc.
  • Generex Biotechnology Corp.
  • Biodel, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17079

The Global Non-Injectable Insulin Market is projected to expand from USD 3.69 Billion in 2025 to USD 6.46 Billion by 2031, registering a CAGR of 9.78%. This market sector focuses on alternative administration routes, including pulmonary inhalation and oral formulations, aimed at delivering insulin without invasive needles. The core catalyst for this growth is the increasing global prevalence of diabetes alongside the urgent necessity to enhance patient adherence among those experiencing needle phobia or injection fatigue. Data from the International Diabetes Federation indicates that approximately 589 million adults worldwide were living with diabetes in 2025, a vast patient population that drives significant demand for convenient therapeutic alternatives capable of overcoming the physical and psychological hurdles of traditional subcutaneous delivery.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.69 Billion
Market Size 2031USD 6.46 Billion
CAGR 2026-20319.78%
Fastest Growing SegmentDrug Stores
Largest MarketNorth America

Despite the evident benefits for patient quality of life, the market confronts a major obstacle regarding the reduced bioavailability of non-injectable forms compared to standard injectables. This physiological constraint typically requires higher dosage amounts to attain equivalent therapeutic results, which significantly elevates manufacturing expenses and the ultimate cost to the patient. Consequently, strict reimbursement frameworks and the substantial economic burden associated with these treatments serve as primary barriers that could hinder widespread clinical uptake and restrict market growth in regions sensitive to cost.

Market Driver

The primary factor driving the non-injectable insulin industry is the rising global incidence of diabetes mellitus, which intensifies the need to improve patient compliance among those burdened by the psychological and physical aspects of daily injections. This increasing disease prevalence demands scalable, user-friendly therapies that alleviate needle phobia. Projections from the International Diabetes Federation's 'IDF Diabetes Atlas 11th Edition' in 2025 estimate that the adult diabetic population will rise to roughly 853 million by 2050, emphasizing the critical need for alternative delivery systems. The magnitude of this demand is reflected in major pharmaceutical operations; for example, Novo Nordisk reported serving over 45.2 million individuals with serious chronic diseases in 2024, illustrating the massive scale of the patient base awaiting less invasive treatment methods.

Concurrently, the sector is being advanced by increased investment in research and development for alternative insulin formulations. Pharmaceutical companies are aggressively funding innovations in inhaled and oral delivery systems to surmount historical bioavailability issues and enhance therapeutic effectiveness. These financial commitments are essential for moving new technologies from clinical trials to commercial reality. A notable example occurred in February 2025, when Oramed Pharmaceuticals announced a strategic joint venture with a combined capital contribution of $75 million to expedite the development and commercialization of its oral insulin platform. Such significant capital injections confirm the industry's dedication to non-invasive solutions and are projected to fuel the next phase of market expansion by making pain-free insulin administration achievable.

Market Challenge

The principal impediment to the growth of the Global Non-Injectable Insulin Market is the physiological issue of lower bioavailability in pulmonary and oral formulations relative to standard injectables. Since these alternative delivery methods face difficulties in efficiently permeating biological barriers, manufacturers are required to formulate drugs with considerably larger amounts of active insulin to guarantee the patient receives the requisite therapeutic dose. This necessity for increased active pharmaceutical ingredients directly raises production costs, leading to a significantly higher end-price that restricts accessibility for both insurers and patients.

This price disparity creates a major obstacle in regions where healthcare budgets are already under severe strain. Rigid reimbursement policies frequently prioritize lower-cost traditional injectables, leaving costlier non-injectable options without sufficient coverage. The scale of this economic pressure is highlighted by recent statistics on the financial impact of the disease; according to the International Diabetes Federation, global health expenditure due to diabetes reached at least 1 trillion US dollars in 2025. Given these massive existing costs, payers remain hesitant to adopt premium-priced therapies, thereby limiting widespread clinical acceptance and impeding market growth in cost-sensitive areas.

Market Trends

The market is being reshaped by a focus on Ultra-Rapid Acting Inhaled Insulin, which prioritizes formulations that replicate the physiological insulin spike of a healthy pancreas more precisely than traditional subcutaneous injections. This trend emphasizes optimizing the aerodynamic particle size of dry powder formulations to guarantee deep lung deposition and rapid systemic absorption, thereby mitigating the risk of post-prandial hyperglycemia. Manufacturers are effectively converting this pharmacokinetic benefit into commercial success, confirming the demand for rapid-onset non-invasive alternatives. For instance, MannKind Corporation reported in its 'Third Quarter 2024 Financial Results' in November 2024 that Afrezza net revenue rose to $15.0 million, indicating a clear growth trajectory for inhaled therapeutics fueled by rising patient demand and better gross-to-net adjustments.

Concurrently, innovation in Buccal and Sublingual Insulin Sprays is gathering speed as researchers utilize novel peptide carriers to traverse the mucosal barrier without the degradation problems associated with gastrointestinal delivery. This trend focuses on creating liquid formulations administered under the tongue, where high vascularization permits direct entry into the bloodstream, bypassing the hepatic first-pass metabolism that frequently neutralizes oral medications. This technological advancement is directly meeting the needs of substantial national patient populations looking for pain-free options. As noted by the University of British Columbia in the June 2024 article 'UBC-developed oral insulin drops offer relief for diabetes patients,' these new sublingual drops are specifically designed to assist the 11.7 million Canadians living with diabetes or pre-diabetes, underscoring the vast regional market potential for such mucosal delivery innovations.

Key Market Players

  • Midatech Pharma Plc
  • Shreya Life Sciences Pvt. Ltd.
  • Boston Therapeutics, Inc.
  • Coromed, Inc.
  • Diabetology Ltd.
  • Emisphere Technologies, Inc.
  • Oramed Pharmaceuticals, Inc.
  • Diasome Pharmaceuticals, Inc.
  • Generex Biotechnology Corp.
  • Biodel, Inc.

Report Scope

In this report, the Global Non-Injectable Insulin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Injectable Insulin Market, By Product

  • Pills
  • Sprays
  • and Others

Non-Injectable Insulin Market, By Distribution Channel

  • Hospital Pharmacies
  • and Online Pharmacies
  • Drug Stores

Non-Injectable Insulin Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-Injectable Insulin Market.

Available Customizations:

Global Non-Injectable Insulin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Injectable Insulin Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Pills, Sprays, and Others)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, and Online Pharmacies, Drug Stores)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Non-Injectable Insulin Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Non-Injectable Insulin Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Non-Injectable Insulin Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Non-Injectable Insulin Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Distribution Channel

7. Europe Non-Injectable Insulin Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Non-Injectable Insulin Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Non-Injectable Insulin Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Non-Injectable Insulin Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Non-Injectable Insulin Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Non-Injectable Insulin Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Non-Injectable Insulin Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Non-Injectable Insulin Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Non-Injectable Insulin Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Non-Injectable Insulin Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Non-Injectable Insulin Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Non-Injectable Insulin Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Non-Injectable Insulin Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Non-Injectable Insulin Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Non-Injectable Insulin Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Non-Injectable Insulin Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Distribution Channel

10. South America Non-Injectable Insulin Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Non-Injectable Insulin Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Non-Injectable Insulin Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Non-Injectable Insulin Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Non-Injectable Insulin Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Midatech Pharma Plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Shreya Life Sciences Pvt. Ltd.
  • 15.3. Boston Therapeutics, Inc.
  • 15.4. Coromed, Inc.
  • 15.5. Diabetology Ltd.
  • 15.6. Emisphere Technologies, Inc.
  • 15.7. Oramed Pharmaceuticals, Inc.
  • 15.8. Diasome Pharmaceuticals, Inc.
  • 15.9. Generex Biotechnology Corp.
  • 15.10. Biodel, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer